Merck & Company (MRK) 60.11 $MRK
Global Multiple Sclerosis Drugs Market 2014-2018 Featuring Bayer, Biogen Idec, Merck Serono, Novartis & Teva Pharmaceutical
M2 - Mon Sep 01, 5:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vfkpw2/global_multiple) has announced the addition of the "Global Multiple Sclerosis Drugs Market 2014-2018" report to their offering. The Global Multiple Sclerosis Drugs market to grow at a CAGR of 5.56 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Multiple Sclerosis Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used for the treatment of multiple sclerosis. One of the emerging trends in the market is the introduction of disease-modifying drugs as a treatment option. Drugs such as Copaxone (Glatiramer Acetate) by Teva Pharmaceuticals and Tysabri (Natalizumab) by Biogen Idec are increasingly used in the treatment of multiple sclerosis. According to the report, the launch of products for treating multiple sclerosis is expected to drive the market during the forecast period of 2013-2018. There is a lucrative space for companies that can address the issue of unmet medical needs in the market. Further, the report states that one of the major challenges in the Global Multiple Sclerosis Drugs market is the unknown etiology of the disease. This has made difficult for medical researchers to develop drugs that target the main source of the disease. Key Questions Answered in this Report - What will the market size be in 2018 and what will the growth rate be? - What are the Key Market Trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? Market Drivers/Challenges/Trends - Unmet Medical Needs - Unknown Etiology of the Disease - Introduction of Disease-modifying Drugs Key Vendors - Bayer - Biogen Idec - Merck Serono - Novartis - Teva Pharmaceutical Other Prominent Vendors - AB Science - Abbvie - Acorda - Active Biotech - GlaxoSmithKline - Glenmark - Mitsubishi Tanabe - Opexa - Pfizer - Sanofi For more information visit http://www.researchandmarkets.com/research/vf...l_multiple
4 Biotechs That Might Be Bought Soon
at Investor's Business Daily - Fri Aug 29, 10:53AM CDT
The recent announcement that Roche (RHHBY) will buy InterMune (ITMN) for $8.3 billion brought new life to M&A speculation in the biotech industry, which had been relatively neglected as the buzz focused on tax-inversion deals by biopharmaceutical...
Dow 30 Stock Roundup: UTX Reiterates Guidance, BA Wins $8.8B Order - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Aug 29, 10:16AM CDT
The Dow had a mixed week following mixed earnings results and concerns about the situation in Ukraine.
Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical
PR Newswire Europe - Fri Aug 29, 7:37AM CDT
DUBLIN, Aug. 29, 2014 /PRNewswire/ -- Research and Markets [http://www.researchandmarkets.com/research/z9b74c/global_multiple] has announced the addition of the "Global Multiple Sclerosis Drugs Market 2014-2018" [http://www.researchandmarkets.com/research/z9b74c/global_multiple] report to their offering.
Drug Discovery Technologies - A Global Market Overview
M2 - Fri Aug 29, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dtdx3f/drug_discovery) has announced the addition of the "Drug Discovery Technologies - A Global Market Overview" report to their offering. The development of new drugs for treating difficult diseases, such as cancer requires extensive expenditure, in addition to consuming a lot of time. The first step in designing a new drug involves the utilizing high-throughput screening of large chemical libraries for identifying compounds that can provide the requisite therapeutic effect. The capability of visualizing biological activity at the cellular level has constituted a strategic component in drug discovery, and adding automation and high-volume screening methods has enabled in testing compounds in large numbers. The field of pharmaceutical research is being provided considerable impetus through the combination of imaging and screening. Key Topics Covered: PART A: GLOBAL MARKET PERSPECTIVE 1. INTRODUCTION 2. KEY MARKET TRENDS 3. RECENT PATENTS IN DRUG DISCOVERY LANDSCAPE 4. KEY GLOBAL PLAYERS 5. KEY BUSINESS TRENDS 6. GLOBAL MARKET OVERVIEW PART B: REGIONAL MARKET PERSPECTIVE 1. THE UNITED STATES 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART C: GUIDE TO THE INDUSTRY 1. NORTH AMERICA 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART
ANNEXURE 1. RESEARCH METHOLOGY 2. FEEDBACK Companies Mentioned: - 4-Antibody AG - Abbott Laboratories - Accelrys, Inc. - Affymetrix Inc. - Agilent Technologies Inc. - Asahi Kasei Pharma Corporation - Astrazeneca Plc - Aviva Biosciences Corp. - Bayer Healthcare AG - BD Biosciences - Beckman Coulter Inc. - Biacore International AB - Bioanalytical Systems, Inc. - Bio-Rad Laboratories, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Caliper Life Sciences, Inc. - Caprion Proteomics, Inc. - Celera Corporation - Celgene Corporation - Charles River Laboratories International, Inc. - Compugen Ltd. - Decode Genetics, Inc. - EMD Millipore Corporation - Evotec AG - GE Healthcare Ltd. - Genedata AG - Hitgen Ltd - Hudson Robotics, Inc. - Illumina Inc. - Incyte Corporation - Isis Pharmaceuticals, Inc. - Kyowa Hakko Kirin Co., Ltd. - Luminex Corporation - Maxcyte, Inc - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Molecular Devices, LLC - Molecular Discovery Ltd. - Molecular Discovery Systems Pty., Ltd. - New England Biolabs, Inc. - Novartis AG - Osiris Therapeutics Inc. - Perkinelmer, Inc. - Promega Corporation - Qiagen N.V. - Quantum Pharmaceuticals - Roche Holding AG - Shimadzu Corporation - Sigma-Aldrich Corporation - Sri Biosciences - Tecan Group Ltd. - The National Center for Drug Screening - Thermo Fisher Scientific Inc. - Viva Biotech Ltd - Waters Corp. For more information visit http://www.researchandmarkets.com/research/dt..._discovery
Global Peptic Ulcer Drugs Market 2014-2018: Key Vendors are AstraZeneca, Eisai, Daewoong and Takeda
M2 - Fri Aug 29, 3:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hx23pt/global_peptic) has announced the addition of the "Global Peptic Ulcer Drugs Market 2014-2018" report to their offering. A peptic ulcer is an open lesion that develops on the mucosal lining of the stomach and small intestine because of the caustic effect of the gastric acids and enzymes in these organs. The symptoms of peptic ulcers are pain in the abdomen, nausea, vomiting, and bloated stomach. The major symptoms include bleeding from the ulcer, which can be life-threatening. It is detected by bloody and sticky stools, often black in color. Peptic ulcers are caused mainly by a Helicobacter pylori infection followed by the overuse of OTC NSAIDs such as Naproxen, Aspirin and Ibuprofen. Peptic ulcers can be of two types based on the site of the ulcer: gastric ulcer and duodenal ulcer. The analysts forecast the Global Peptic Ulcer Drugs market to grow at a CAGR of 2.9 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Peptic Ulcer Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of peptic ulcers that are available in the market. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Product Profiles 05. Market Research Methodology 06. Introduction 07. Market Landscape 08. Pipeline Portfolio 09. Market Segmentation by Class of Drugs 10. Geographical Segmentation 11. Buying Criteria 12. Market Growth Drivers 13. Drivers and their Impact 14. Market Challenges 15. Impact of Drivers and Challenges 16. Market Trends 17. Trends and their Impact 18. Vendor Landscape 19. Key Vendor Analysis Companies Mentioned: - AstraZeneca plc - Eisai Co. Ltd. - Daewoong Pharmaceutical Co. Ltd. - Takeda Pharmaceutical Co. Ltd. - Daiichi Sankyo - Dr. Reddy's Laboratories - Eumedica - Ferring Pharmaceuticals - Horizon Pharma - Johnson and Johnson - Merck Sharp and Dohme - Otsuka Holdings - Pfizer - PharmaKing - Pozen - Rottapharm Madaus - Taiho Pharmaceutical - Zeria Pharmaceutical and Zuventus Healthcare For more information visit http://www.researchandmarkets.com/research/hx...bal_peptic
Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014
M2 - Fri Aug 29, 3:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gr3rvm/global_peptide) has announced the addition of the "Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014" report to their offering. The conventional methods developed to prevent and eradicate the prevalence of cancer have achieved limited success in cancer treatment. These methods are confined to low specificity, safety and large number of side effects, which prompted the researchers to look for a better solution. It has been discovered that peptides can be used for effective and viable treatment of cancer without having disadvantages of conventional methods. The quintessential for using peptide cancer therapeutics is that they have high specificity, safety and efficacy which is not provide by therapeutics available in market. The completion of human genome sequencing has helped in the research and development of peptide cancer therapeutics. The data allowed the researchers to look deep into the root cause of cancer hidden in human genome. This has allowed targeting cancer cells with high accuracy; thus, increasing the probability of treatment with high success rates. Using this data several novel molecules are being developed, which will have higher stability, effective delivery and minimal or no side-effects. Peptide cancer therapeutics has edge in treating rare type of cancers. Conventional approaches of cancer treatments are unable to treat them successfully. Sometimes these approaches cannot be used due to unspecificity or they are not effective at all. For instance, brain cancer is a rare type of cancer that falls in this category. Key Topics Covered: 1. Introduction to Peptide Cancer Therapeutics 2. Mechanism of Peptide Cancer Therapeutics 3. Peptide Cancer Therapeutics Market Outlook 4. Peptide Cancer Therapeutics Market Dynamics 5. Peptide Cancer Therapeutics Market Future Growth Prospects 6. Peptide Cancer Drug Clinical Pipeline by Phase, Indication, Company & Country 7. Marketed Peptide Cancer Drug Insight by Indication, Country & Company 8. Suspended & Discontinued Peptide Cancer Drug in Clinical Trial by Phase, Indication, Company & Country 9. Competitive Landscape Companies Mentioned: - AngioChem - Antigen Express - Amgen - GlaxoSmithKline - Galena Biopharma - Ipsen - Merck - PeptiDream - Roche - Sanofi For more information visit http://www.researchandmarkets.com/research/gr...al_peptide
US CNS Disorders Drug Pipeline Insight 2014
M2 - Fri Aug 29, 3:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j85brc/us_cns_disorders) has announced the addition of the "US CNS Disorders Drug Pipeline Insight 2014" report to their offering. The Central Nervous System (CNS) disorders market in US is one of the largest segments of pharmaceuticals industry. The numbers of CNS disorders have increased at an alarming rate, while the available therapies were unable to meet the market requirements. There has been steady to rapid growth in the market for CNS disorder, especially over the past two decades. The market for CNS therapies is one of the largest therapeutic categories and also one of the fastest growing. US account for more than 55% of the global CNS Disorders drugs market. Within the CNS market, the biggest therapeutic area is the market for anti-psychotics, followed by anti-depressive and mood stab markets. Anti-epileptic and anti-Alzheimer's markets come next while other classes of drugs have a marginal share. Antipsychotics have a market share of nearly 30% while antidepressants corner about 25% of the market. Anti convulsants have about 17% of the market share while drugs used in Alzheimer's Disease form about 9% of the market, with ADHD and narcolepsy drugs medications have about 7% market share. The other classes of drugs have market shares of less than 5% each. Key Topics Covered: 1. Introduction to Central Nervous System (CNS) Disorder 2. US Central Nervous System (CNS) Disorder Market Overview 3. US Central Nervous System (CNS) Disorder Incidence by Disease 4. US Central Nervous System (CNS) Disorder Market Dynamics 5. US Multiple CNS Disorder Drug Pipeline by Phase & Company 6. US Alzheimer's Disease Drug Pipeline by Phase & Company 7. US Multiple Sclerosis Drug Pipeline by Phase & Company 8. US Parkinson's Disease Drug Pipeline by Phase & Company 9. US CNS Disorder/Neurodegenerative Disorders Drug Pipeline by Phase & Company 10. US Epilepsy Drug Pipeline by Phase & Company 11. US Migraine Drug Pipeline by Phase & Company 12. US Huntington's Disease Drug Pipeline by Phase & Company 13. US Neuropathic Pain Clinical Pipeline by Phase & Company 14. US Schizophrenia Clinical Trial Insight by Phase & Company 15. US Sleep Disorders Drug Pipeline by Phase & Company 16. Competitive Landscape Companies Mentioned: - Alkermes - Allergan - AstraZeneca - Biogen Idec - Bristol-Myers Squibb - Eli Lilly - GlaxoSmithKline - Merck - Novartis - Pfizer - Roche - Sanofi - Sunovion Pharmaceuticals - Teva Pharmaceutical For more information visit http://www.researchandmarkets.com/research/j8..._disorders
Has Gilead Sciences, Inc.'s Star Drug Already Peaked?
Brian Orelli, The Motley Fool - Motley Fool - Thu Aug 28, 7:00PM CDT
Gilead Sciences ' hepatitis C drug scored $3.5 billion in sales in the second quarter, but prescriptions have been falling since before the quarter closed. First, new prescriptions started to fall in March. And then, as you'd expect, total...
Acquisitions, Appointment, and Vaccine Recommendations - Research Reports on InterMune, Amgen, Johnson & Johnson, Merck and Medtronic
PR Newswire - Thu Aug 28, 8:30AM CDT
Today, Analysts Review released its research reports regarding InterMune Inc. (NASDAQ: ITMN), Amgen, Inc. (NASDAQ: AMGN), Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK) and Medtronic, Inc. (NYSE: MDT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6042-100free.
3 Reasons Merck & Co., Inc.'s Stock Could Fall
Sean Williams, The Motley Fool - Motley Fool - Thu Aug 28, 8:05AM CDT
If you were lucky enough to time your purchase of Merck during the heights of the Great Recession, your investment has probably seen a return of 100% or greater. Unfortunately, timing the stock market is practically impossible to do, and as you...
Compact, Easy-to-Use Steritest(TM) Symbio Pumps from Merck Millipore Leverage Industry Leading Technology for Improved Sterility Testing
PR Newswire Europe - Thu Aug 28, 3:00AM CDT
- Improves workflows and increases reliability with new ergonomic design
USIBC Concludes Successful Pharmaceutical Mission to India; Looks Forward to Continued Dialogue and Collaboration with the Government of India
Business Wire - Wed Aug 27, 10:46AM CDT
The U.S.-India Business Council (USIBC) has concluded its Pharmaceutical Executive Mission to Delhi, India. The delegation expressed its commitment to the Indian market, called for further dialogue with the government on issues related to pricing and intellectual property, and discussed strategies for expanding greater access to healthcare and health insurance in India. USIBC's Executive Mission was led by Paul Schaper, Executive Director, Global Health Policy, Merck and included senior representatives from Johnson & Johnson, Baxter, Mylan, Abbott, Eli Lilly, Waston, and Quintiles.
Human Vaccine Technologies Market 2014-2018 - Key Insights into the $43 Billion Industry
M2 - Wed Aug 27, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hl3zqh/human_vaccine) has announced the addition of the "Human Vaccine Technologies Market" report to their offering. The global vaccine market projected to rise to $43.5 billion by 2018, growing at a CAGR of 12.65% Rapid advances in understanding of the immune system and desire of medical community to engineer both preventive and therapeutic vaccines for a wide spectrum of diseases are fueling changes in medicine and in the managed care industry. The growth of global Vaccine market is partly fuelled scientific breakthroughs such as genome sequencing of infectious pathogens, refined understanding of the immune system and its mechanism of response, followed by significant influx of money from public funding bodies, private charity and commercial organizations. Safety, demonstration of sufficiently high efficacy and lack of a consistent evaluation/development pathway are major stumbling blocks for development of new vaccines. The application of modern biological technologies and advances in genomics has resulted in novel concepts like reverse vaccinology, DNA vaccines, recombinant subunit vaccines and non-replicating vectors, some of these concepts have already progressed to advanced clinical trials and new products such as the meningococcal and hepatitis B vaccine. Recently, cancer and certain autoimmune disorders have received attention as targets for both prophylactic and therapeutic vaccines. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Market Analysis 4. Vaccine Technologies Market, by End-User 5. Vaccine Technologies Market, by Type 6. Vaccine Technologies Market, by Class 7. Vaccine Technology Market, by Disease Indication 8. Regional Market Analysis 9. Company Developments 10. Major Company Profiles - Alphavax - Antigen Express, INC. - Bavarian Nordic - Genticel - Glaxo Smithkline PLC - Liquidia Technologies - Merck & CO., INC. - Novartis AG - Pfizer, INC. - Sanofi For more information visit http://www.researchandmarkets.com/research/hl...an_vaccine
Will This Coverage Initiation Affect Merck (MRK) Stock Today?
at The Street - Wed Aug 27, 8:21AM CDT
Deutsche initiated coverage on Merck (MRK) with a "hold" rating and a $63 price target based on valuation.
SeeThruEquity Issues Quarterly Update on Manhattan Scientifics, Highlighting Spencer Falk's Lead Role in MRX Commercialization Efforts
ACCESSWIRE - Wed Aug 27, 8:01AM CDT
New York, NY / ACCESSWIRE / August 27, 2014 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a quarterly update on Manhattan Scientifics, Inc. (OTCQB: MHTX) for Q2 2014.
Merck Serono Announces Groundbreaking of New Pharmaceutical Manufacturing Facility in China, its Second Largest Worldwide
PR Newswire Europe - Wed Aug 27, 5:41AM CDT
NANTONG, China, August 27, 2014 /PRNewswire/ --
Cell Separation Technologies Market Report 2013-2019 - Immunology, Stem Cell, Cancer & Neuroscience Research
M2 - Wed Aug 27, 5:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kt78rv/cell_separation) has announced the addition of the "Cell Separation Technologies Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Separation based on surface markers has the highest market share in the technology segment of overall cell separation technologies market. Rapidly developing technologies entering in the market are ultimately expanding application area of cell separation technologies and therefore driving the global cell separation technologies market towards growth. The global cell separation technologies market is consolidated in nature with very few companies competing head to head in the market. Giant international players control this market with their patented technologies and predatory growth strategies. Proprietary products based on patented technologies are limiting the entry and growth of new market players entering into the global cell separation technologies market. Geographically, North America is leading the global cell separation technologies market and is closely followed by Europe. Factors fueling growth of cell separation technologies market in North America include existence of highly developed research infrastructure, availability of research funding, availability of highly developed technologies, higher rates of implementing newer techniques in the practice and higher healthcare spending. Asia-Pacific is lucrative market for cell separation technologies. Factors that are estimated to flourish the cell separation technologies market in Asia-Pacific include, increasing government initiatives to strengthen biotechnology industry in the countries namely, India and China on the grounds of rapidly growing medical tourism industry in the respective countries and increased cancer research funding by the Australian government. Availability of government funds for research in the Asia-Pacific region, existence of poor patient population best suited for clinical trials and availability of cheap and skilled manpower are attracting global researchers to this region. On the other hand, stringent regulatory frameworks are restricting the entry of new market players in the cell separation technologies market in this region. The global cell separation technologies market is segmented as follows: Cell Separation Technologies Market, by Technology - Gradient centrifugation - Separation based on surface markers - Magnetic activated cell sorting (MACS) - Fluorescence activated cell sorting (FACS) Cell Separation Technologies Market, by Application - Stem cell research - Immunology - Neuroscience research - Cancer research Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Cell Separation Technologies Market Overview Chapter 4 Global Cell Separation Technologies Market, by Technology Chapter 5 Global Cell Separation Technologies Market, by Application Chapter 6 Global Cell Separation Technologies Market, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles - BD Biosciences - Life Technologies Corporation - Merck Millipore - Miltenyi Biotec GmbH - pluriSelect GmbH - STEMCELL Technologies, Inc. - Terumo BCT, Inc. For more information visit http://www.researchandmarkets.com/research/kt...separation
Global Male Infertility Market (Techniques and Geography) Report 2014-2020
M2 - Wed Aug 27, 2:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4n33x3/global_male) has announced the addition of the "Global Male Infertility Market (Techniques and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2012 - 2020" report to their offering. The male infertility market is expected to grow to $301.5 million by 2020 with a CAGR of 4.9% during 2013-2020 Male infertility is defined as the inability of a male to impregnate his female partner after a year of unprotected intercourse. 20% of the total infertility is due to male factors. The major factors driving the male infertility market are the change in lifestyle, increasing age, environmental effects, etc., and these factors are majorly contributing to the rise in male infertility levels. The major limitation experienced in the male infertility market is due to repeated treatment failures leading to an emotional impact on the patient. The repeated failures would compel most patients to discontinue the treatment. The other limitation is the social taboo. Out of 32-40% infertile men, only 15% of the men opt for the treatment for infertility due to the embarrassment, guilt, etc. The opportunity driving the market is medical tourism and increase in awareness about male infertility. The treatment for male infertility is expensive; however, the cost of the treatment is expected to decrease with the advancement in treatment technologies. The other factor that may drag the prices lower would be the patients' expectations for cost effective treatments. These factors would drive the male infertility market. MARKET BY TECHNIQUES - DNA Fragmentation Technique - Oxidative Stress Analysis - Microscopic Examination - Sperm Penetration Assay - Sperm Agglutination - Computer Assisted Semen Analysis - Others Companies Mentioned - Access Pharmaceuticals - Andrology Solutions. - ASKA Pharmaceutical Co. Ltd - Cordex Pharma - Halotech DNA SL - Intas Pharmaceuticals Ltd. - Merck Serono - Pantarhei Bioscience B - SCSA diagnostics - ZydusCadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/4n...lobal_male
Global Multiple Sclerosis Drugs Market 2014-2018 Featuring Bayer, Biogen Idec, Merck Serono, Novartis & Teva Pharmaceutical
M2 - Mon Sep 01, 5:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vfkpw2/global_multiple) has announced the addition of the "Global Multiple Sclerosis Drugs Market 2014-2018" report to their offering. The Global Multiple Sclerosis Drugs market to grow at a CAGR of 5.56 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Multiple Sclerosis Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used for the treatment of multiple sclerosis. One of the emerging trends in the market is the introduction of disease-modifying drugs as a treatment option. Drugs such as Copaxone (Glatiramer Acetate) by Teva Pharmaceuticals and Tysabri (Natalizumab) by Biogen Idec are increasingly used in the treatment of multiple sclerosis. According to the report, the launch of products for treating multiple sclerosis is expected to drive the market during the forecast period of 2013-2018. There is a lucrative space for companies that can address the issue of unmet medical needs in the market. Further, the report states that one of the major challenges in the Global Multiple Sclerosis Drugs market is the unknown etiology of the disease. This has made difficult for medical researchers to develop drugs that target the main source of the disease. Key Questions Answered in this Report - What will the market size be in 2018 and what will the growth rate be? - What are the Key Market Trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? Market Drivers/Challenges/Trends - Unmet Medical Needs - Unknown Etiology of the Disease - Introduction of Disease-modifying Drugs Key Vendors - Bayer - Biogen Idec - Merck Serono - Novartis - Teva Pharmaceutical Other Prominent Vendors - AB Science - Abbvie - Acorda - Active Biotech - GlaxoSmithKline - Glenmark - Mitsubishi Tanabe - Opexa - Pfizer - Sanofi For more information visit http://www.researchandmarkets.com/research/vf...l_multiple
4 Biotechs That Might Be Bought Soon
at Investor's Business Daily - Fri Aug 29, 10:53AM CDT
The recent announcement that Roche (RHHBY) will buy InterMune (ITMN) for $8.3 billion brought new life to M&A speculation in the biotech industry, which had been relatively neglected as the buzz focused on tax-inversion deals by biopharmaceutical...
Dow 30 Stock Roundup: UTX Reiterates Guidance, BA Wins $8.8B Order - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Aug 29, 10:16AM CDT
The Dow had a mixed week following mixed earnings results and concerns about the situation in Ukraine.
Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical
PR Newswire Europe - Fri Aug 29, 7:37AM CDT
DUBLIN, Aug. 29, 2014 /PRNewswire/ -- Research and Markets [http://www.researchandmarkets.com/research/z9b74c/global_multiple] has announced the addition of the "Global Multiple Sclerosis Drugs Market 2014-2018" [http://www.researchandmarkets.com/research/z9b74c/global_multiple] report to their offering.
Drug Discovery Technologies - A Global Market Overview
M2 - Fri Aug 29, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dtdx3f/drug_discovery) has announced the addition of the "Drug Discovery Technologies - A Global Market Overview" report to their offering. The development of new drugs for treating difficult diseases, such as cancer requires extensive expenditure, in addition to consuming a lot of time. The first step in designing a new drug involves the utilizing high-throughput screening of large chemical libraries for identifying compounds that can provide the requisite therapeutic effect. The capability of visualizing biological activity at the cellular level has constituted a strategic component in drug discovery, and adding automation and high-volume screening methods has enabled in testing compounds in large numbers. The field of pharmaceutical research is being provided considerable impetus through the combination of imaging and screening. Key Topics Covered: PART A: GLOBAL MARKET PERSPECTIVE 1. INTRODUCTION 2. KEY MARKET TRENDS 3. RECENT PATENTS IN DRUG DISCOVERY LANDSCAPE 4. KEY GLOBAL PLAYERS 5. KEY BUSINESS TRENDS 6. GLOBAL MARKET OVERVIEW PART B: REGIONAL MARKET PERSPECTIVE 1. THE UNITED STATES 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART C: GUIDE TO THE INDUSTRY 1. NORTH AMERICA 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART
ANNEXURE 1. RESEARCH METHOLOGY 2. FEEDBACK Companies Mentioned: - 4-Antibody AG - Abbott Laboratories - Accelrys, Inc. - Affymetrix Inc. - Agilent Technologies Inc. - Asahi Kasei Pharma Corporation - Astrazeneca Plc - Aviva Biosciences Corp. - Bayer Healthcare AG - BD Biosciences - Beckman Coulter Inc. - Biacore International AB - Bioanalytical Systems, Inc. - Bio-Rad Laboratories, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Caliper Life Sciences, Inc. - Caprion Proteomics, Inc. - Celera Corporation - Celgene Corporation - Charles River Laboratories International, Inc. - Compugen Ltd. - Decode Genetics, Inc. - EMD Millipore Corporation - Evotec AG - GE Healthcare Ltd. - Genedata AG - Hitgen Ltd - Hudson Robotics, Inc. - Illumina Inc. - Incyte Corporation - Isis Pharmaceuticals, Inc. - Kyowa Hakko Kirin Co., Ltd. - Luminex Corporation - Maxcyte, Inc - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Molecular Devices, LLC - Molecular Discovery Ltd. - Molecular Discovery Systems Pty., Ltd. - New England Biolabs, Inc. - Novartis AG - Osiris Therapeutics Inc. - Perkinelmer, Inc. - Promega Corporation - Qiagen N.V. - Quantum Pharmaceuticals - Roche Holding AG - Shimadzu Corporation - Sigma-Aldrich Corporation - Sri Biosciences - Tecan Group Ltd. - The National Center for Drug Screening - Thermo Fisher Scientific Inc. - Viva Biotech Ltd - Waters Corp. For more information visit http://www.researchandmarkets.com/research/dt..._discovery Global Peptic Ulcer Drugs Market 2014-2018: Key Vendors are AstraZeneca, Eisai, Daewoong and Takeda
M2 - Fri Aug 29, 3:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hx23pt/global_peptic) has announced the addition of the "Global Peptic Ulcer Drugs Market 2014-2018" report to their offering. A peptic ulcer is an open lesion that develops on the mucosal lining of the stomach and small intestine because of the caustic effect of the gastric acids and enzymes in these organs. The symptoms of peptic ulcers are pain in the abdomen, nausea, vomiting, and bloated stomach. The major symptoms include bleeding from the ulcer, which can be life-threatening. It is detected by bloody and sticky stools, often black in color. Peptic ulcers are caused mainly by a Helicobacter pylori infection followed by the overuse of OTC NSAIDs such as Naproxen, Aspirin and Ibuprofen. Peptic ulcers can be of two types based on the site of the ulcer: gastric ulcer and duodenal ulcer. The analysts forecast the Global Peptic Ulcer Drugs market to grow at a CAGR of 2.9 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Peptic Ulcer Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of peptic ulcers that are available in the market. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Product Profiles 05. Market Research Methodology 06. Introduction 07. Market Landscape 08. Pipeline Portfolio 09. Market Segmentation by Class of Drugs 10. Geographical Segmentation 11. Buying Criteria 12. Market Growth Drivers 13. Drivers and their Impact 14. Market Challenges 15. Impact of Drivers and Challenges 16. Market Trends 17. Trends and their Impact 18. Vendor Landscape 19. Key Vendor Analysis Companies Mentioned: - AstraZeneca plc - Eisai Co. Ltd. - Daewoong Pharmaceutical Co. Ltd. - Takeda Pharmaceutical Co. Ltd. - Daiichi Sankyo - Dr. Reddy's Laboratories - Eumedica - Ferring Pharmaceuticals - Horizon Pharma - Johnson and Johnson - Merck Sharp and Dohme - Otsuka Holdings - Pfizer - PharmaKing - Pozen - Rottapharm Madaus - Taiho Pharmaceutical - Zeria Pharmaceutical and Zuventus Healthcare For more information visit http://www.researchandmarkets.com/research/hx...bal_peptic
Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014
M2 - Fri Aug 29, 3:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gr3rvm/global_peptide) has announced the addition of the "Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014" report to their offering. The conventional methods developed to prevent and eradicate the prevalence of cancer have achieved limited success in cancer treatment. These methods are confined to low specificity, safety and large number of side effects, which prompted the researchers to look for a better solution. It has been discovered that peptides can be used for effective and viable treatment of cancer without having disadvantages of conventional methods. The quintessential for using peptide cancer therapeutics is that they have high specificity, safety and efficacy which is not provide by therapeutics available in market. The completion of human genome sequencing has helped in the research and development of peptide cancer therapeutics. The data allowed the researchers to look deep into the root cause of cancer hidden in human genome. This has allowed targeting cancer cells with high accuracy; thus, increasing the probability of treatment with high success rates. Using this data several novel molecules are being developed, which will have higher stability, effective delivery and minimal or no side-effects. Peptide cancer therapeutics has edge in treating rare type of cancers. Conventional approaches of cancer treatments are unable to treat them successfully. Sometimes these approaches cannot be used due to unspecificity or they are not effective at all. For instance, brain cancer is a rare type of cancer that falls in this category. Key Topics Covered: 1. Introduction to Peptide Cancer Therapeutics 2. Mechanism of Peptide Cancer Therapeutics 3. Peptide Cancer Therapeutics Market Outlook 4. Peptide Cancer Therapeutics Market Dynamics 5. Peptide Cancer Therapeutics Market Future Growth Prospects 6. Peptide Cancer Drug Clinical Pipeline by Phase, Indication, Company & Country 7. Marketed Peptide Cancer Drug Insight by Indication, Country & Company 8. Suspended & Discontinued Peptide Cancer Drug in Clinical Trial by Phase, Indication, Company & Country 9. Competitive Landscape Companies Mentioned: - AngioChem - Antigen Express - Amgen - GlaxoSmithKline - Galena Biopharma - Ipsen - Merck - PeptiDream - Roche - Sanofi For more information visit http://www.researchandmarkets.com/research/gr...al_peptide
US CNS Disorders Drug Pipeline Insight 2014
M2 - Fri Aug 29, 3:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j85brc/us_cns_disorders) has announced the addition of the "US CNS Disorders Drug Pipeline Insight 2014" report to their offering. The Central Nervous System (CNS) disorders market in US is one of the largest segments of pharmaceuticals industry. The numbers of CNS disorders have increased at an alarming rate, while the available therapies were unable to meet the market requirements. There has been steady to rapid growth in the market for CNS disorder, especially over the past two decades. The market for CNS therapies is one of the largest therapeutic categories and also one of the fastest growing. US account for more than 55% of the global CNS Disorders drugs market. Within the CNS market, the biggest therapeutic area is the market for anti-psychotics, followed by anti-depressive and mood stab markets. Anti-epileptic and anti-Alzheimer's markets come next while other classes of drugs have a marginal share. Antipsychotics have a market share of nearly 30% while antidepressants corner about 25% of the market. Anti convulsants have about 17% of the market share while drugs used in Alzheimer's Disease form about 9% of the market, with ADHD and narcolepsy drugs medications have about 7% market share. The other classes of drugs have market shares of less than 5% each. Key Topics Covered: 1. Introduction to Central Nervous System (CNS) Disorder 2. US Central Nervous System (CNS) Disorder Market Overview 3. US Central Nervous System (CNS) Disorder Incidence by Disease 4. US Central Nervous System (CNS) Disorder Market Dynamics 5. US Multiple CNS Disorder Drug Pipeline by Phase & Company 6. US Alzheimer's Disease Drug Pipeline by Phase & Company 7. US Multiple Sclerosis Drug Pipeline by Phase & Company 8. US Parkinson's Disease Drug Pipeline by Phase & Company 9. US CNS Disorder/Neurodegenerative Disorders Drug Pipeline by Phase & Company 10. US Epilepsy Drug Pipeline by Phase & Company 11. US Migraine Drug Pipeline by Phase & Company 12. US Huntington's Disease Drug Pipeline by Phase & Company 13. US Neuropathic Pain Clinical Pipeline by Phase & Company 14. US Schizophrenia Clinical Trial Insight by Phase & Company 15. US Sleep Disorders Drug Pipeline by Phase & Company 16. Competitive Landscape Companies Mentioned: - Alkermes - Allergan - AstraZeneca - Biogen Idec - Bristol-Myers Squibb - Eli Lilly - GlaxoSmithKline - Merck - Novartis - Pfizer - Roche - Sanofi - Sunovion Pharmaceuticals - Teva Pharmaceutical For more information visit http://www.researchandmarkets.com/research/j8..._disorders
Has Gilead Sciences, Inc.'s Star Drug Already Peaked?
Brian Orelli, The Motley Fool - Motley Fool - Thu Aug 28, 7:00PM CDT
Gilead Sciences ' hepatitis C drug scored $3.5 billion in sales in the second quarter, but prescriptions have been falling since before the quarter closed. First, new prescriptions started to fall in March. And then, as you'd expect, total...
Acquisitions, Appointment, and Vaccine Recommendations - Research Reports on InterMune, Amgen, Johnson & Johnson, Merck and Medtronic
PR Newswire - Thu Aug 28, 8:30AM CDT
Today, Analysts Review released its research reports regarding InterMune Inc. (NASDAQ: ITMN), Amgen, Inc. (NASDAQ: AMGN), Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK) and Medtronic, Inc. (NYSE: MDT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6042-100free.
3 Reasons Merck & Co., Inc.'s Stock Could Fall
Sean Williams, The Motley Fool - Motley Fool - Thu Aug 28, 8:05AM CDT
If you were lucky enough to time your purchase of Merck during the heights of the Great Recession, your investment has probably seen a return of 100% or greater. Unfortunately, timing the stock market is practically impossible to do, and as you...
Compact, Easy-to-Use Steritest(TM) Symbio Pumps from Merck Millipore Leverage Industry Leading Technology for Improved Sterility Testing
PR Newswire Europe - Thu Aug 28, 3:00AM CDT
- Improves workflows and increases reliability with new ergonomic design
USIBC Concludes Successful Pharmaceutical Mission to India; Looks Forward to Continued Dialogue and Collaboration with the Government of India
Business Wire - Wed Aug 27, 10:46AM CDT
The U.S.-India Business Council (USIBC) has concluded its Pharmaceutical Executive Mission to Delhi, India. The delegation expressed its commitment to the Indian market, called for further dialogue with the government on issues related to pricing and intellectual property, and discussed strategies for expanding greater access to healthcare and health insurance in India. USIBC's Executive Mission was led by Paul Schaper, Executive Director, Global Health Policy, Merck and included senior representatives from Johnson & Johnson, Baxter, Mylan, Abbott, Eli Lilly, Waston, and Quintiles.
Human Vaccine Technologies Market 2014-2018 - Key Insights into the $43 Billion Industry
M2 - Wed Aug 27, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hl3zqh/human_vaccine) has announced the addition of the "Human Vaccine Technologies Market" report to their offering. The global vaccine market projected to rise to $43.5 billion by 2018, growing at a CAGR of 12.65% Rapid advances in understanding of the immune system and desire of medical community to engineer both preventive and therapeutic vaccines for a wide spectrum of diseases are fueling changes in medicine and in the managed care industry. The growth of global Vaccine market is partly fuelled scientific breakthroughs such as genome sequencing of infectious pathogens, refined understanding of the immune system and its mechanism of response, followed by significant influx of money from public funding bodies, private charity and commercial organizations. Safety, demonstration of sufficiently high efficacy and lack of a consistent evaluation/development pathway are major stumbling blocks for development of new vaccines. The application of modern biological technologies and advances in genomics has resulted in novel concepts like reverse vaccinology, DNA vaccines, recombinant subunit vaccines and non-replicating vectors, some of these concepts have already progressed to advanced clinical trials and new products such as the meningococcal and hepatitis B vaccine. Recently, cancer and certain autoimmune disorders have received attention as targets for both prophylactic and therapeutic vaccines. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Market Analysis 4. Vaccine Technologies Market, by End-User 5. Vaccine Technologies Market, by Type 6. Vaccine Technologies Market, by Class 7. Vaccine Technology Market, by Disease Indication 8. Regional Market Analysis 9. Company Developments 10. Major Company Profiles - Alphavax - Antigen Express, INC. - Bavarian Nordic - Genticel - Glaxo Smithkline PLC - Liquidia Technologies - Merck & CO., INC. - Novartis AG - Pfizer, INC. - Sanofi For more information visit http://www.researchandmarkets.com/research/hl...an_vaccine
Will This Coverage Initiation Affect Merck (MRK) Stock Today?
at The Street - Wed Aug 27, 8:21AM CDT
Deutsche initiated coverage on Merck (MRK) with a "hold" rating and a $63 price target based on valuation.
SeeThruEquity Issues Quarterly Update on Manhattan Scientifics, Highlighting Spencer Falk's Lead Role in MRX Commercialization Efforts
ACCESSWIRE - Wed Aug 27, 8:01AM CDT
New York, NY / ACCESSWIRE / August 27, 2014 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a quarterly update on Manhattan Scientifics, Inc. (OTCQB: MHTX) for Q2 2014.
Merck Serono Announces Groundbreaking of New Pharmaceutical Manufacturing Facility in China, its Second Largest Worldwide
PR Newswire Europe - Wed Aug 27, 5:41AM CDT
NANTONG, China, August 27, 2014 /PRNewswire/ --
Cell Separation Technologies Market Report 2013-2019 - Immunology, Stem Cell, Cancer & Neuroscience Research
M2 - Wed Aug 27, 5:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kt78rv/cell_separation) has announced the addition of the "Cell Separation Technologies Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Separation based on surface markers has the highest market share in the technology segment of overall cell separation technologies market. Rapidly developing technologies entering in the market are ultimately expanding application area of cell separation technologies and therefore driving the global cell separation technologies market towards growth. The global cell separation technologies market is consolidated in nature with very few companies competing head to head in the market. Giant international players control this market with their patented technologies and predatory growth strategies. Proprietary products based on patented technologies are limiting the entry and growth of new market players entering into the global cell separation technologies market. Geographically, North America is leading the global cell separation technologies market and is closely followed by Europe. Factors fueling growth of cell separation technologies market in North America include existence of highly developed research infrastructure, availability of research funding, availability of highly developed technologies, higher rates of implementing newer techniques in the practice and higher healthcare spending. Asia-Pacific is lucrative market for cell separation technologies. Factors that are estimated to flourish the cell separation technologies market in Asia-Pacific include, increasing government initiatives to strengthen biotechnology industry in the countries namely, India and China on the grounds of rapidly growing medical tourism industry in the respective countries and increased cancer research funding by the Australian government. Availability of government funds for research in the Asia-Pacific region, existence of poor patient population best suited for clinical trials and availability of cheap and skilled manpower are attracting global researchers to this region. On the other hand, stringent regulatory frameworks are restricting the entry of new market players in the cell separation technologies market in this region. The global cell separation technologies market is segmented as follows: Cell Separation Technologies Market, by Technology - Gradient centrifugation - Separation based on surface markers - Magnetic activated cell sorting (MACS) - Fluorescence activated cell sorting (FACS) Cell Separation Technologies Market, by Application - Stem cell research - Immunology - Neuroscience research - Cancer research Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Cell Separation Technologies Market Overview Chapter 4 Global Cell Separation Technologies Market, by Technology Chapter 5 Global Cell Separation Technologies Market, by Application Chapter 6 Global Cell Separation Technologies Market, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles - BD Biosciences - Life Technologies Corporation - Merck Millipore - Miltenyi Biotec GmbH - pluriSelect GmbH - STEMCELL Technologies, Inc. - Terumo BCT, Inc. For more information visit http://www.researchandmarkets.com/research/kt...separation
Global Male Infertility Market (Techniques and Geography) Report 2014-2020
M2 - Wed Aug 27, 2:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4n33x3/global_male) has announced the addition of the "Global Male Infertility Market (Techniques and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2012 - 2020" report to their offering. The male infertility market is expected to grow to $301.5 million by 2020 with a CAGR of 4.9% during 2013-2020 Male infertility is defined as the inability of a male to impregnate his female partner after a year of unprotected intercourse. 20% of the total infertility is due to male factors. The major factors driving the male infertility market are the change in lifestyle, increasing age, environmental effects, etc., and these factors are majorly contributing to the rise in male infertility levels. The major limitation experienced in the male infertility market is due to repeated treatment failures leading to an emotional impact on the patient. The repeated failures would compel most patients to discontinue the treatment. The other limitation is the social taboo. Out of 32-40% infertile men, only 15% of the men opt for the treatment for infertility due to the embarrassment, guilt, etc. The opportunity driving the market is medical tourism and increase in awareness about male infertility. The treatment for male infertility is expensive; however, the cost of the treatment is expected to decrease with the advancement in treatment technologies. The other factor that may drag the prices lower would be the patients' expectations for cost effective treatments. These factors would drive the male infertility market. MARKET BY TECHNIQUES - DNA Fragmentation Technique - Oxidative Stress Analysis - Microscopic Examination - Sperm Penetration Assay - Sperm Agglutination - Computer Assisted Semen Analysis - Others Companies Mentioned - Access Pharmaceuticals - Andrology Solutions. - ASKA Pharmaceutical Co. Ltd - Cordex Pharma - Halotech DNA SL - Intas Pharmaceuticals Ltd. - Merck Serono - Pantarhei Bioscience B - SCSA diagnostics - ZydusCadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/4n...lobal_male
